Latest Insider Transactions at Kiora Pharmaceuticals Inc (KPRX)
This section provides a real-time view of insider transactions for Kiora Pharmaceuticals Inc (KPRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of KIORA PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of KIORA PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2024
|
Carmine N. Stengone Director |
BUY
Open market or private purchase
|
Direct |
1,250
+50.0%
|
$3,750
$3.68 P/Share
|
|
Sep 10
2024
|
Aron Shapiro Director |
BUY
Open market or private purchase
|
Indirect |
3,000
+50.0%
|
$9,000
$3.6 P/Share
|
|
Aug 19
2024
|
Lisa Walters Hoffert Director |
BUY
Open market or private purchase
|
Direct |
1,250
+50.0%
|
$3,750
$3.86 P/Share
|
|
Aug 19
2024
|
Praveen Tyle Director |
BUY
Open market or private purchase
|
Direct |
5,000
+49.93%
|
$15,000
$3.96 P/Share
|
|
Aug 14
2024
|
Melissa Tosca CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+12.82%
|
$6,000
$3.21 P/Share
|
|
Jul 01
2024
|
Eric Joseph Daniels Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,355
+28.36%
|
-
|
|
Jul 01
2024
|
Melissa Tosca CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,620
+39.65%
|
-
|
|
Jul 01
2024
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,629
+34.13%
|
-
|
|
Jun 14
2024
|
Melissa Tosca CFO |
BUY
Open market or private purchase
|
Direct |
100
+2.45%
|
$500
$5.25 P/Share
|
|
Jun 14
2024
|
Eric Joseph Daniels Chief Development Officer |
BUY
Open market or private purchase
|
Direct |
1,431
+11.31%
|
$7,155
$5.29 P/Share
|
|
Jun 13
2024
|
Brian M. Strem President and CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+17.11%
|
$15,000
$5.0 P/Share
|
|
Jun 13
2024
|
Erin Parsons Director |
BUY
Open market or private purchase
|
Indirect |
5,260
+50.0%
|
$21,040
$4.88 P/Share
|
|
Sep 29
2023
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+41.95%
|
-
|
|
Sep 29
2023
|
Eric Joseph Daniels Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+41.44%
|
-
|
|
Sep 29
2023
|
Melissa Tosca CFO |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+46.23%
|
-
|
|
Mar 03
2023
|
Eric Joseph Daniels Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,600
+37.65%
|
-
|
|
Mar 03
2023
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,600
+35.15%
|
$46,800
$3.83 P/Share
|
|
Mar 03
2023
|
Melissa Tosca CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,400
+24.49%
|
-
|
|
Oct 21
2022
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+48.67%
|
-
|
|
Oct 21
2022
|
Melissa Tosca CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Oct 21
2022
|
Eric Joseph Daniels Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+49.41%
|
-
|
|
Feb 10
2022
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-0.47%
|
$0
$0.69 P/Share
|
|
Jan 05
2022
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
326
-0.48%
|
$326
$1.08 P/Share
|
|
Jan 05
2022
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
114
-0.5%
|
$114
$1.08 P/Share
|
|
Dec 07
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
91
-0.39%
|
$91
$1.3 P/Share
|
|
Dec 07
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-0.4%
|
$273
$1.3 P/Share
|
|
Nov 18
2021
|
Brian M. Strem President and CEO |
BUY
Open market or private purchase
|
Direct |
17,853
+39.48%
|
$17,853
$1.41 P/Share
|
|
Nov 02
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-0.36%
|
$83
$1.98 P/Share
|
|
Nov 02
2021
|
Brenda Mann VP of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
62
-0.41%
|
$62
$1.98 P/Share
|
|
Nov 02
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
250
-0.36%
|
$250
$1.98 P/Share
|
|
Oct 21
2021
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,517
+50.0%
|
-
|
|
Oct 04
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
249
-0.36%
|
$498
$2.01 P/Share
|
|
Oct 04
2021
|
Brenda Mann VP of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
62
-0.41%
|
$124
$2.01 P/Share
|
|
Oct 04
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-0.36%
|
$166
$2.01 P/Share
|
|
Sep 02
2021
|
Brenda Mann VP of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
61
-0.4%
|
$61
$1.81 P/Share
|
|
Sep 02
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-0.36%
|
$84
$1.81 P/Share
|
|
Sep 02
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
253
-0.37%
|
$253
$1.81 P/Share
|
|
Aug 03
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
87
-0.37%
|
$174
$2.4 P/Share
|
|
Aug 03
2021
|
Brenda Mann VP of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
63
-0.41%
|
$126
$2.4 P/Share
|
|
Aug 03
2021
|
Michael P. Manzo VP of Engineering |
SELL
Payment of exercise price or tax liability
|
Direct |
65
-0.42%
|
$130
$2.4 P/Share
|
|
Aug 03
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
261
-0.38%
|
$522
$2.4 P/Share
|
|
Aug 02
2021
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
192,775
-19.72%
|
$385,550
$2.4 P/Share
|
|
Jul 30
2021
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
68,188
-6.52%
|
$136,376
$2.69 P/Share
|
|
Jul 29
2021
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,000
-27.66%
|
$1,200,000
$3.0 P/Share
|
|
Jul 28
2021
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
375,443
-20.61%
|
$1,126,329
$3.28 P/Share
|
|
Jul 27
2021
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,377,695
-15.03%
|
$11,888,475
$5.47 P/Share
|
|
Jul 27
2021
|
Armistice Capital, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
852,500
+16.88%
|
$3,410,000
$4.8 P/Share
|
|
Jul 02
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
877
-1.25%
|
$2,631
$3.7 P/Share
|
|
Jul 02
2021
|
Brenda Mann VP of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
154
-0.99%
|
$462
$3.7 P/Share
|
|
Jul 02
2021
|
Michael P. Manzo VP of Engineering |
SELL
Payment of exercise price or tax liability
|
Direct |
160
-1.03%
|
$480
$3.7 P/Share
|